Vise Technologies Inc. Invests $655,000 in Krystal Biotech, Inc. $KRYS

Vise Technologies Inc. purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 1,762 shares of the company’s stock, valued at approximately $655,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Western Wealth Management LLC purchased a new stake in Krystal Biotech during the 1st quarter worth approximately $34,000. Greenline Wealth Management LLC purchased a new position in shares of Krystal Biotech in the fourth quarter valued at approximately $34,000. UMB Bank n.a. lifted its position in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares in the last quarter. Global Retirement Partners LLC boosted its stake in shares of Krystal Biotech by 788.9% in the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after acquiring an additional 142 shares during the last quarter. Finally, USA Financial Formulas acquired a new stake in shares of Krystal Biotech in the first quarter worth approximately $44,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $346.58 on Monday. The company’s 50-day moving average is $347.03 and its two-hundred day moving average is $301.54. Krystal Biotech, Inc. has a 1-year low of $136.73 and a 1-year high of $382.54. The firm has a market capitalization of $10.26 billion, a price-to-earnings ratio of 43.43 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on KRYS. Jefferies Financial Group reiterated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research report on Monday, July 13th. Citigroup lifted their target price on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Finally, Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Krystal Biotech presently has an average rating of “Moderate Buy” and an average price target of $365.40.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the sale, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 51,642 shares of company stock worth $16,471,923. Company insiders own 13.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.